Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15967486 | 0.84 | LPL (0.31) | LPLLIPG | |
| SCHEMBL8737458 | 0.80 | LPL (0.36) | LPLLIPG | |
| SCHEMBL106003 | 0.79 | TDP1 (0.35) | — | |
| SCHEMBL24457824 | 0.76 | LPL (0.36) | LPLLIPG | |
| SCHEMBL106726 | 0.72 | CYP3A4 (0.46) | LPLLIPG | |
| SCHEMBL29503402 | 0.72 | CYP3A4 (0.46) | LPLLIPG | |
| SCHEMBL29842912 | 0.71 | LPL (0.40) | LPLLIPG | |
| SCHEMBL190545 | 0.71 | LPL (0.40) | LPLLIPG | |
| SCHEMBL1431415 | 0.71 | CYP3A4 (0.33) | — | |
| SCHEMBL3720446 | 0.71 | LIPE (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964642-B1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2017-11-15 | — | — | EP | disclosed |
| US-9663494-B2 | Inhibitors of bruton's tyrosine kinase | HOFFMANN-LA ROCHE INC. (US) | 2017-05-30 | — | — | US | disclosed |
| EP-2964642-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. Hoffmann-La Roche AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-20150376166-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | HOFFMANN-LA ROCHE INC. (US) | 2015-12-31 | — | — | US | disclosed |
| WO-2014135474-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
| EP-2205564-B1 | NOVEL KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2014-07-30 | — | — | EP | disclosed |
| EP-2426109-B1 | NOVEL KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-12-18 | — | — | EP | disclosed |
| EP-2426109-A1 | NOVEL KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-03-07 | — | — | EP | disclosed |
| US-7943618-B2 | Btk protein kinase inhibitors | ROCHE PALO ALTO LLC (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2205564-A1 | NOVEL KINASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009053269-A1 | NOVEL KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| US-20090105209-A1 | BTK protein kinase inhibitors | ROCHE PALO ALTO LLC | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105209-A1 | BTK protein kinase inhibitors | BTK, SYK, LYN | LPL 3465/4885LIPG 3362/4885 |
| US-20150376166-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | LPL 2462/4885LIPG 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.